Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shaily Engineering Plastics Limited is an Indian contract development and manufacturing organization (CDMO) specializing in precision-engineered plastic components for medical devices and pharmaceutical delivery systems. The company operates manufacturing facilities in India serving global pharmaceutical and medical device OEMs, with core competencies in injection molding, clean room assembly, and regulatory compliance (ISO 13485, FDA-registered). Strong revenue growth (22% YoY) and margin expansion reflect increasing penetration of high-value medical device contracts and operational leverage from capacity utilization.
Shaily operates as a B2B supplier with multi-year contracts to pharmaceutical and medical device OEMs. Revenue model combines: (1) per-unit manufacturing fees with volume commitments, (2) tooling and development fees for new programs, and (3) value-added assembly services. Pricing power derives from high switching costs (regulatory validation requirements, quality certifications), technical expertise in complex molding tolerances, and co-location advantages for Indian pharmaceutical clients. Gross margins of 42% reflect specialized capabilities versus commodity plastics manufacturers. Operating leverage is high due to fixed costs in clean room infrastructure, quality systems, and regulatory compliance - incremental volume flows through at 60%+ contribution margins once capacity utilization exceeds 70%.
New contract wins with global pharmaceutical/medical device OEMs (multi-year programs worth $10-50M annually)
Capacity utilization rates and operating margin expansion (target 35%+ operating margins at 80%+ utilization)
Regulatory approvals and facility certifications (FDA inspections, ISO renewals, customer audits)
Customer concentration risk and renewal of top 5 customer contracts (likely 50-60% of revenue)
Rupee/USD exchange rate movements (export revenue sensitivity to currency fluctuations)
Regulatory compliance risk - FDA warning letters, failed inspections, or quality issues can halt production and terminate customer contracts, with 12-24 month remediation timelines
Customer concentration - Top 5-10 customers likely represent 60-70% of revenue; loss of anchor client would require 18-24 months to replace volume
Geographic concentration in India - Regulatory changes, labor availability, or infrastructure constraints in Gujarat/Maharashtra manufacturing hubs could disrupt operations
Competition from established global CDMOs (Gerresheimer, West Pharmaceutical, Aptar) with broader geographic footprints and larger R&D budgets
Customer backward integration - Large pharmaceutical companies may insource critical component manufacturing to control supply chains and reduce costs
Pricing pressure from Chinese manufacturers offering lower-cost alternatives, though regulatory barriers provide some protection
High capex requirements (9% of revenue) to maintain growth trajectory could strain cash flow if contract wins slow or utilization disappoints
Working capital intensity from tooling inventory and long customer payment terms (60-90 days typical) requires careful cash management
Currency mismatch - Export revenue in USD/EUR while costs primarily in INR creates translation risk if rupee strengthens significantly
low - Medical device and pharmaceutical end markets are non-discretionary with stable demand through economic cycles. However, customer R&D budgets and new product launches can slow during severe recessions. Indian pharmaceutical export dynamics (60% of global generic supply) provide structural tailwinds independent of developed market GDP growth.
moderate - Rising US rates impact valuation multiples for high-growth healthcare stocks (current 36x EV/EBITDA compresses with higher discount rates). Operationally, capex financing costs increase, though 0.30 debt/equity suggests limited balance sheet sensitivity. Customer capital allocation for new device programs may slow if cost of capital rises significantly, delaying contract awards by 6-12 months.
minimal - B2B contracts with investment-grade pharmaceutical companies minimize receivables risk. Working capital requirements are predictable, and the company maintains 1.24x current ratio. No significant exposure to consumer credit or financing operations.
growth - 62% net income growth, 22% revenue growth, and 28.5% ROE attract growth investors seeking exposure to India's pharmaceutical manufacturing ecosystem and global medical device outsourcing trends. High valuation (36x EV/EBITDA, 15x P/B) reflects premium growth expectations. Recent 23% three-month drawdown suggests profit-taking after 52% one-year gain, creating entry opportunity for momentum investors.
high - Small-cap healthcare stock with limited float and institutional ownership concentration. Beta likely 1.3-1.5x relative to Indian equity indices. Quarterly earnings volatility from lumpy contract timing and customer order patterns. Currency fluctuations add 5-10% quarterly revenue variability.
